• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien’s Stellarex drug-eluting balloon wins CE Mark

Covidien’s Stellarex drug-eluting balloon wins CE Mark

January 9, 2015 By Brad Perriello

Covidien's Stellarex drug-eluting balloon wins CE Mark

European regulators granted market clearance for Covidien‘s (NYSE:COV) Stellarex drug-eluting balloon for treating peripheral artery disease, the company said today.

Covidien is due to sell the Stellarex assets to Spectranetics (NSDQ:SPNC) as soon as its $43 billion merger with Medtronic (NYSE:MDT) closes, which is expected to occur later this month or in early February.

"PAD is a progressive disease that affects millions of people around the world. [Drug-eluting balloons] are emerging as an alternative to traditional treatment options, such as angioplasty or stenting, because of their ability to restore blood flow, prevent the reoccurrence of new blockages and preserve future treatment options," principal investigator Dr. Henrik Schröeder of Berlin’s Jewish Hospital said in prepared remarks. "In clinical trials, the Stellarex [DEB] has demonstrated promising results with strong patency rates and low reoccurrence of target lesions at 24 months."

The $30 million deal for Stellarex covers the Stellarex angioplasty platform, a paclitaxel-eluting balloon used to treat peripheral artery disease. When the deal was announced Spectranetics said it expected to launch the Stellarex device as soon as it won CE Mark approval, which at time was forecast for late 2014 or early this year.

The device, which uses a drug coating called EnduraCoat designed to prevent drug loss during the procedure, could hit the U.S. market in 2017, the companies said at the time.

Earlier this week, both Medtronic’s and Covidien’s shareholders voted to approve their merger, which must be cleared by the Irish High Court before it can be consummated.

Filed Under: Mergers & Acquisitions, News Well, Regulatory/Compliance Tagged With: CE Mark, Covidien, Medtronic buys Covidien, Peripheral, Spectranetics Corp.

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy